glp 1 agonist and dpp 4 inhibitor DPP4 Inhibitors vs GLP-1 Agonists | June 2021 | Clinical Corner Therapeutic Effects of GLP-1 Receptor

Fast Absorption: Quickly and easily integrate this supplement into your routineno waiting around for results

In animal research, BPC-157 has demonstrated consistent regenerative effects across multiple tissue types

Key findings: CagriSema achieved up to 23% weight loss at 84 weeks Tirzepatide showed numerical superiority (~25.5%) The trial did not meet non-inferiority vs tirzepatide Clinical interpretation: Despite not meeting the primary endpoint, an important signal emerges: targeting multiple biological pathways remains a compelling strategy Why this matters: Reinforces obesity as a complex neuroendocrine disease Supports the concept that multi-hormonal approaches may better impact the defended weight set point Moves the field closer to precision, mechanism-based therapies Safety: Consistent with the GLP-1 class Mainly gastrointestinal adverse events, generally mild to moderate and transient Whats next: Ongoing development with higher-dose CagriSema Expansion of the REDEFINE program FDA decision expected by late 2026 Take-home message: The future of obesity treatment lies not in a single pathway, but in strategically combining mechanisms to sustainably shift weight biology

Effectiveness and safety analysis of ketogenic diet therapy for drug-resistant epilepsy caused by structural pathology

Primary study outcomes included: 1) Volume of alcohol consumed, and participants blood alcohol levels during a laboratory-based alcohol self-administration paradigm at baseline and end of treatment in which participants were provided with their preferred alcoholic drink and brand and could elect to delay drinking for up to 50 minutes for monetary payments